- Supported exchanges /
- F /
- 6VX.F
HEALIOS K.K. (6VX F) stock market data APIs
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
HEALIOS K.K. Financial Data Overview
| 1.15 | |
| 1.15 | |
| - | |
| 1.15 | |
| 1.15 | |
| 0.66-1.53 | |
| 110 M | |
| 90 130 K | |
| 521 M | |
| 0.906 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
HEALIOS K.K. Fundamental Data is available in our Financial Data APIs
- Net Revenue 521 M
- EBITDA -3 008 999 936
- Earnings Per Share -0.41
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get HEALIOS K.K. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get HEALIOS K.K. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
